Discovery of Rapidly Adapting Antibody Opens Door for Universal Flu Vaccines
With flu season rapidly advancing, attention will shift to what novel ideas scientists have developed to protect public health. Now, it would seem investigators at the Dana-Farber Cancer Institute are looking to take the lead in this critical discussion because they have recently published data on the discovery of a new type of immune antibody that can evolve rapidly to neutralize a broad range of influenza virus strains—including those the body hasn’t yet encountered. The revelation of the body’s ability to make the adaptable antibody suggests potential strategies for creating improved or even universal influenza vaccines.
Medicilon Appoints Dr. Liu Jian as President of Drug Discovery Division
Medicilon, a one-stop pharmaceutical preclinical R&D service platform CRO, recognizes the importance of drug discovery as the cornerstone of new drug innovation. With extensive expertise in modern synthetic chemistry, Medicilon excels in various cutting-edge areas of pharmaceutical research, including chiral drugs, glycochemistry, antibodies and antibody-drug conjugates (ADC), nucleoside/nucleotide drugs, and oligonucleotide drugs (such as RNAi). Additionally, Medicilon has made significant advancements in PROTAC technology and established a progressively improved BSL-2 laboratory facility.